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Prostaglandinsareimportantmediatorsandmodulatorsoftheinﬂammatoryresponsetoinfection.Theprostaglandinsparticipate
in the pathogenesis of hemodynamic collapse, organ failure, and overwhelming inﬂammation that characterize severe sepsis and
shock. In light of this, cyclooxygenase (COX) inhibiting pharmacological agents have been extensively studied for their capacity
to ameliorate the aberrant physiological and immune responses during severe sepsis. Animal models of sepsis, using the systemic
administration of pathogen-associated molecular patterns (PAMPs) or live pathogens, have been used to examine the eﬀectiveness
ofCOXinhibitionasatreatmentforseveresepsis.Thesestudieshavelargelyshownbeneﬁcialeﬀectsonmortality.However,human
studies have failed to show clinical utility of COX inhibitor treatment in severely septic patients. Why this approach “worked” in
animals but not in humans might reﬂect diﬀerences in the controlled nature of animal investigations compared to human studies.
This paper contrasts the impact of COX inhibitors on mortality in animal models of sepsis and human studies of sepsis and
examines potential reasons for diﬀerences between these two settings.
1.Introduction
Sepsisisamajorcauseofmorbidityandmortalityworldwide
[1], with more than 750,000 cases per year in the United
States alone [2]. Despite improvements in diagnosis and
therapeutics, there is an ongoing need for better treatments.
Sepsis can be deﬁned as a “systemic illness caused by
microbial invasion of normally sterile parts of the body”
[2], and it can be complicated by organ dysfunction (severe
sepsis) or hypotension refractory to volume resuscitation
(septic shock) [2].
Research into the fundamental mechanisms of sepsis
has historically depended on animal models, with two pri-
mary approaches taken to model severe sepsis or septic
shock. In one approach, live pathogens are used to cause
sepsis. Examples of this approach include (1) inoculating the
bloodstream or peritoneal cavity of animals with a single
bacterial pathogen, (2) inducing peritonitis via cecal ligation
and puncture (CLP), or (3) inoculating the peritoneal cavity
of animals with fecal matter. The other approach induces
the inﬂammatory response and complications of sepsis but
is not truly sepsis since live pathogens are not utilized. In this
approach,animalsareexposed,usuallyviaintravenousinjec-
tion, to pathogen-associated molecular patterns (PAMPs)
that trigger robust inﬂammatory responses by activating
pathogen recognition receptor-based signaling cascades in
the host. Typical PAMPs used to model sepsis include lipo-
polysaccharide (LPS) from Gram-negative bacteria, pepti-
doglycan, or mixed PAMPs delivered as inactivated (dead)
bacteria.
Animal models of sepsis foster the in vivo investigation of
signaling cascades that mediate this process. Over the past 50
years, lipid mediators known as prostaglandins (PGs) have
garnered signiﬁcant attention for their roles in mediating
the inﬂammatory and immune response to severe infection.
The PGs, oxygenated metabolites of arachidonic acid, are
small molecules that have a myriad of roles in regulating
pathophysiological responses during sepsis. The synthesis,
catabolism, and signaling of PGs have been studied as targets
in treating sepsis, particularly when used in combination
with antimicrobial agents and supportive care. Early studies
targeting PG synthesis in the treatment of sepsis involved2 Mediators of Inﬂammation
inhibiting the cyclooxygenase (COX) enzymes, the ﬁrst
committed enzymatic step in the metabolism of arachidonic
acid into bioactive PGs [3, 4].
Despite encouraging results in animal models of sepsis
and shock, human pharmacological trials of COX inhibitors
have not provided consistent or signiﬁcantly beneﬁcial ﬁnd-
ings. The failure of COX inhibitors to signiﬁcantly improve
the outcome of humans with sepsis strongly dampened en-
thusiasm for targeting PG synthesis for this problem. Why
this approach “worked” in animals but not in humans likely
reﬂects important diﬀerences in the controlled nature of
the investigations involving the former compared to the
latter. This unstructured paper explores the impact of COX
inhibitors on mortality in animal models of sepsis and
human studies of sepsis and examines potential reasons
for diﬀerences between these two settings. The possibilities
for future use of PG-based strategies for treating sepsis are
discussed.
2. Methods
Literature Review. Studies addressing the use of COX
inhibitors and nonsteroidal anti-inﬂammatory drugs
(NSAIDs) in animal and human studies of sepsis were
identiﬁed using the PubMed database (National Library
of Medicine, Bethesda, MD). The following search terms
were used alone and in combination: “sepsis,” “infection,”
“cyclooxygenase,” “prostaglandins,” “PGE2,” “receptors,” and
“hemodynamic”. Additional references were identiﬁed with-
in the bibliographies of PubMed-identiﬁed manuscripts.
Searches were done for all available publication dates up
until January 31, 2012.
Studies were included for analysis if COX inhibitors
were administered to animals prior to or in response to the
systemic (intravenous or intraperitoneal) administration of
PAMPs or if COX inhibitors were administered to animals
prior to or in response to a systemic infection model of
sepsis. Such sepsis models with live organisms included both
monomicrobial sepsis models, where a single species of bac-
teria was administered to animals systemically (intravenous
or intraperitoneal) and polymicrobial sepsis models, where
animals were infected with undeﬁned mixtures of organisms
either through the intraperitoneal introduction of stool or
through CLP. Studies involving mice genetically deﬁcient for
COX isoforms were included as indicated. Human studies
were included if COX inhibitors were administered to treat
sepsis as deﬁned by the authors of the studies.
The major outcome reviewed from these studies was
the eﬀect of COX inhibitors on mortality. Only studies that
included data regarding mortality were included for such
analyses.
3. Results
3.1. PAMP Models of Sepsis in Animals. A total of 43
manuscripts were identiﬁed that modeled sepsis in animals
using the systemic administration of PAMPs to induce a
physiological and immunological response similar to clinical
sepsis [3–45]. There were 16 publications that did not report
mortality data and were excluded from analysis [4–6, 8, 10,
13, 16, 17, 22, 26, 28–31, 36, 41]. Thus, 27 manuscripts
were included that provided data regarding mortality after
systemic PAMP exposure. Notably, two studies actually
conducted studies on two types of species [23, 25], bringing
the total number of studies evaluated to 29.
Mortality was assessed in seven diﬀerent animal species
across these studies (Figure 1(a)). Of these, 27 used LPS
alone as the sepsis-inducing agent, while one study admin-
istered heat-killed Corynebacterium parvum prior to LPS
[15] and one study used heat-killed Group B Streptococcus
[34]. The source of the LPS was usually Escherichia coli
but ﬁve studies used Salmonella LPS [4, 14, 25, 27, 45].
The PAMPs were usually delivered intravenously, although
intraperitoneal approaches were also used. There was great
heterogeneity among studies for the COX inhibitor used, the
dose employed, whether the drug was administered before
or after PAMP exposure, the route of administration of the
drugs, and the number of doses of the COX inhibitor. A
majority of studies used dual COX-1/COX-2 inhibitors but
one study used isoform selective inhibitors [30]. One study
was selected that did not use a COX inhibitor but a knockout
of the COX-2 gene in mice [12].
The ﬁrst animal study identiﬁed that examined the
impact of COX inhibitors on PAMP-induced sepsis was
a dog study published in 1962 by Northover and Subra-
manian [4]. This study was conducted before it was well
established that antipyretic and analgesic agents function as
COX inhibitors. Thus, the rationale for that work was that
salicylate antipyretic agents (sodium salicylate and acetylsal-
icylic acid) might function as inhibitors of certain protease
enzymesthought(atthetime)tomediatehostcardiovascular
responses during bacterial sepsis [4]. While the authors
examinedactionsoftheseagentsonthehemodynamiceﬀects
of Salmonella LPS, they did not report on the eﬀects of these
medications on mortality. Such data were reported, however,
in a 1967 study using acetylsalicylic acid in dogs exposed to
E. coli LPS [3]. That study showed that acetylsalicylic acid
signiﬁcantly reduced the lethality of LPS in the dog model
[3].
In total, the studies identiﬁed for this paper demon-
strated that COX inhibition, and genetic COX-2 deletion
[12], improved survival in 21 of 29 studies (72.4%) [3, 7, 9,
11,12,14,18–21,24,27,32,34,37,39,40,42,44,45],caused
no change in survival in 7 studies (24.3%) [15, 23, 33, 38, 43,
46, 47], and reduced survival in a single mouse study (3.4%)
[35].
3.2. Infectious Animal Models of Sepsis. Seventeen studies
were identiﬁed in 16 manuscripts that examined the impact
of either pharmacological or genetic inhibition of COX en-
zymes and infection-induced sepsis [46–61]. There were
three publications that did not report mortality data and
were excluded from analysis [51, 52, 56]. Two studies
included data from COX-2 null mice [53, 54].
The models of sepsis used in these studies included three
mouse CLP studies [46, 53, 60], three rat studies involvingMediators of Inﬂammation 3
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Figure 1: Inﬂuence of COX inhibitors on animal models of sepsis. (a) Studies were reviewed for experiments in which mortality was
assessed for animals treated with COX inhibitors either before or after the systemic administration of pathogen-associated molecular
patterns (generally, lipopolysaccharide). One mouse study (that showed a beneﬁt to survival) included COX-2 knockout animals and not
a pharmacological inhibitor. (b) Studies were reviewed for experiments in which mortality was assessed for animals treated with COX
inhibitors either before or after the induction of systemic infection (see text for details). One mouse study (that showed a reduction in
survival) included COX-2 knockout animals and not a pharmacological inhibitor.
the introduction of feces into the peritoneal cavity [49, 57,
61], two rat studies using systemic infection with live E.
coli [48, 57], one rat study with systemic infection with live
Group B Streptococcus [58], two canine studies with systemic
infection with live E. coli [50, 51], three porcine studies
with systemic infection with live Group B Streptococcus [47,
56, 59], one mouse study with systemic infection with live
Vibrio vulniﬁcus [55], one mouse study using live Group A
Streptococcus [54], and one sheep study of infection with live
E. coli [48].
Ofthe14studiesevaluable,mortalitywasimprovedin10
(71.4%), as depicted in Figure 1(b) [48–50, 54, 57–61].This
included one of the two COX-2 knockout mouse studies
[54]. Two studies showed no eﬀect on mortality of COX
inhibition [46, 47] and two mouse studies revealed increased
death in either COX-inhibitor-treated mice [55]o raC O X - 2
knockout mouse model [53].
3.3. Human Studies of Sepsis. Three studies have examined
theimpact ofCOX inhibitor therapyon mortality in humans
suﬀering from clinically deﬁned sepsis [62–64], and one
study [65] was a subgroup analysis of a larger study [62].
None of the three primary studies showed any positive or
negative impact of COX inhibitors on mortality. Two used
ibuprofen[62,63]andoneusedlornoxicam,adrugrelatively
more potent against COX-2 than COX-1 [64]. The largest
study was conducted by Bernard et al. and randomized 455
subjects to receive ibuprofen 10mg per kilogram (maximal
dose, 800mg) over a period of 30 to 60 minutes every 6
hours for eight doses or placebo [62]. A similar but much
smaller study was conducted by Haupt et al. and randomized
29 patients with sepsis to ibuprofen (600mg or 800mg
intravenously followed by 800mg per rectum every six hrs)
or placebo [63]. The lornoxicam study by Memis ¸e ta l .
included 40 subjects with sepsis randomized to receive either
lornoxicam (8mg administered intravenously every 12hrs
for six doses) or placebo [64].
The ﬁrst human study examining the role of COX
inhibitors in sepsis was conducted by Haupt et al. in
1991[63].Thisrandomized,double-blind,multicenterstudy
included 29 patients with clinical evidence of severe sepsis
(16weregivenibuprofenand13wereadministeredplacebo).
Eight of the ibuprofen-treated patients presented with shock
and seven had the acute respiratory distress syndrome
(ARDS),whilefouroftheplacebo-treatedsubjectshadshock
and four had ARDS. Nine patients in the COX inhibitor
group died (56%) versus four in the placebo group (31%)
(nonsigniﬁcant diﬀerence) [63].
In 1997, Bernard et al. conducted a larger, multicenter
study that also compared ibuprofen with placebo in a
randomized, blinded fashion [62]. There were 224 patients
in the ibuprofen group and 231 in the placebo treatment
arm. Most patients in both groups had two or three organ
systems failing at study entry and nearly 50% of subjects
had pneumonia in both groups [62]. Shock was present in
65% and 63% of patients in the COX inhibitor group and
placebo group, respectively. Thirty-day mortality did not
diﬀer signiﬁcantly in the drug-treatment and placebo groups
(37% versus 40%) [62]. Notably, and perhaps relevant to the4 Mediators of Inﬂammation
ﬁndings of this study, acetaminophen use was permitted in
both arms, and this agent was applied to 44% of subjects in
the placebo group (but only 22% in the ibuprofen group)
[62].
A substudy of this clinical trial was later published by
Arons et al. [65], and it examined hypothermic patients with
sepsis who were treated in a randomized, controlled study of
ibuprofen at a dose of 10mg/kg (maximum 800mg) admin-
istered intravenously every 6hr for eight doses compared
with placebo. There were 44 subjects in that study, of which
13 received ibuprofen [65]. A signiﬁcant reduction in 30-day
mortality rate from 90% (18/20 placebo-treated patients) to
54% (13/24 ibuprofen-treated patients) was observed [65].
In 2004, a randomized, placebo-controlled study of
lornoxicam was conducted by Memis et al. [64]. Of 40
subjects enrolled, half received the COX inhibitor and half
received placebo. Shock was seen on admission in seven
patients in the lornoxicam group and eight in the placebo
group.Theagerangeofsubjectswaswideandsimilarinboth
groups (for the 40 patients, 19–89 years old). Mortality was
35% in the lornoxicam group and 40% in the placebo group
(nonsigniﬁcant diﬀerence) [64].
4. Discussion
Herein we review the impact of COX inhibition on mortality
in animal and human models of sepsis. A major ﬁnding was
that outcomes were better in animal studies than in human
studies. While the reasons for this are unclear, it may be
important for advancing new treatments for sepsis to more
closely explore possible explanations.
When sepsis was modeled in noninfectious, PAMP-
driven animal experiments, mortality was improved by COX
inhibitors, in 72.4% of studies (Figure 1(a)). These studies
spanned seven animal species and only a single mouse study
revealed greater lethality when COX inhibitors were used. It
is possible that heterogeneity in results related to diﬀerences
in the dose and microbial source of PAMPs or the type,
dose,androuteofadministration oftheCOXinhibitors used
among studies. On balance, these data suggest that in addi-
tion to any eﬀects on host defense mechanisms against live
pathogens, COX metabolites increase the mortality resulting
froman overwhelming host inﬂammatory response, possibly
due to their importance in systemic vasodilation and renal
blood ﬂow [66]. Indeed, several of these studies showed
improved hemodynamic parameters in animals treated with
a COX inhibitor [3, 5–7, 10, 13, 17, 19, 21–24, 26, 28, 29, 31,
32, 40, 41, 43].
It is also notable that animals with actual infections
causing sepsis fared better when COX inhibitors were
used (Figure 1(b)). These results could be due to similar
mechanisms that protected animals from PAMP exposure.
However,inthesettingofliveinfection,anotherdeterminant
of outcome is the capacity of the host’s immune system
to eliminate invading pathogens. It is possible that COX
inhibitors couldinﬂuencehostimmune defensemechanisms
since PGs are well known to regulate both innate and
adaptive immunity [67–70].
Clearly, animal studies of infection-related sepsis and
PAMP-associated inﬂammation have been able to demon-
strate a beneﬁt of COX inhibitor use. Why the lack of
eﬀect in human studies? For one, important diﬀerences
exist in the experimental design between animal studies
of sepsis and human clinical trials. It is likely that these
diﬀerences confound potentially beneﬁcial actions of COX
inhibitors in human infection. Animal studies beneﬁt from
uniformity among the treated and control groups. Strong
similarities (or identicalness) exist in parameters that might
impact outcome, including age, gender, genetic background
(in mouse studies particularly), general health, rearing
environment, commensal microbiota. In addition, the insult
(whether infectious or not) is generally highly deﬁned and
uniform in animal studies (e.g., all animals will receive
the same dose of LPS or the same-sized cecal puncture
wound). Animals have also not commonly been treated
with antibiotics or other disease-modifying agents during
studies of sepsis, which might otherwise alter the results.
Lastly, in many animal studies of sepsis, COX inhibitors were
given prior to the onset of overwhelming inﬂammation or
infection, though studies giving the medication after the
onset of sepsis have generally concurred [48, 57, 59, 71].
In stark contrast to the highly controlled animal studies,
human clinical studies suﬀer from variability in almost every
measurable aspect. Subjects with sepsis are not uniform in
age, gender, comorbidities (or the presence of immunosup-
pression), the cause of sepsis (a major diﬀerence), the timing
of therapy relative to the onset of symptoms, and so forth.
Another major diﬀerence is that human subjects receive sup-
portive care beyond that generally administered to animals,
includingintravenousﬂuids,vasopressiveagents,mechanical
ventilation, blood products, surgery, and (perhaps most
importantly) antibiotics. Thus, the lack of impact of COX
inhibitorsinhumanstudiesmaybeduetoalackofsimilarity
within and between cases and controls. It is also possible that
the incremental eﬀect (whether beneﬁcial or detrimental) of
COX inhibitors is too small to measure reliably when other
supportive therapies are making more signiﬁcant impacts on
patient recovery.
The lack of clear beneﬁt for COX inhibitors in human
studies of sepsis begs the question of whether there is any
worthincontinuingtoinvestigatePGsynthesisandsignaling
cascades as targets for sepsis treatment. Given the risk of
“throwingoutthebabywiththebathwater,”itisimportantto
determine whetherthe wealth of animal studies has provided
a clue to novel therapies that remains undiscovered. For
example, COX inhibitors might be most beneﬁcial if given
early in sepsis when patients are otherwise relatively robust:
young, free of comorbidities, and so forth. Unfortunately
such a patient population is a minority in the world of sepsis.
An alternative notion to explain the lack of beneﬁt of
COX inhibitors in human sepsis is that speciﬁc prostanoid
molecules might need to be targeted, as opposed to blocking
the most proximal committed step in PG synthesis. Per-
haps in human cases of sepsis some PGs are helpful and
others maladaptive. This approach has been taken in both
animal and human studies [72]. For example, inhibiting
the synthesis of thromboxane [73, 74] has been attemptedMediators of Inﬂammation 5
in small human studies of sepsis and acute respiratory
distresssyndromewithdisappointingresults.Animalmodels
have been used more extensively to study select COX-
derived eicosanoids [28, 75]. An example is provided by the
molecule PGE2, whose synthesis and signaling is increasingly
being investigated as a target for immunotherapy in severe
infections [54, 76–78].
In summary, myriad highly controlled animal models of
sepsis provide a strong rationale for the targeting of PGs
in the treatment of sepsis. However, the relatively small
number of human studies has failed to support this ap-
proach. While the reasons for these diﬀerences are unclear,
future studies are warranted to identify either particular
human populations who might beneﬁt from COX inhibitor
treatment during sepsis or to identify particular prostanoids
whose synthesis or signaling pathways can be speciﬁcally
targeted during sepsis management.
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